Life Sciences

  • July 24, 2026

    'Irreparable': The Lasting Harm Of Justices' Temporary Orders

    The U.S. Supreme Court has considered dozens of emergency petitions involving executive policies since President Donald Trump's return to office. While justices often defend their emergency rulings as stop-gap measures, people at the center of those cases — who've lost their legal status, jobs, or federal funding — say that even interim decisions have had lasting effects on their lives.

  • July 24, 2026

    Pet Medical Co. Sheds Dog Arthritis Drug Suit For Good

    A New Jersey federal judge has thrown out for good a proposed nationwide class action alleging Zoetis Inc. hid the dangerous side effects of its canine osteoarthritis drug, finding the complaint failed to plead the plaintiffs relied on any misrepresentations to their dogs' detriment.

  • July 24, 2026

    Finch Therapeutics Can Seek Ch. 11 Plan Votes

    A Delaware bankruptcy judge on Friday conditionally approved the disclosure statement for microbiome treatment developer Finch Therapeutics' Chapter 11 plan, allowing it to solicit creditor votes.

  • July 24, 2026

    Novo Asks NJ Judge To Stop Lilly's 'Deceptive' GLP-1 Ads

    Novo Nordisk Inc. asked a New Jersey federal court Friday to block rival Eli Lilly & Co. from running ads allegedly comparing their respective GLP-1 drugs using "outdated" clinical trials and "false superiority messages," arguing the ads are damaging its reputation and misleading consumers.

  • July 24, 2026

    Fenwick, Latham Lead Scribe Therapeutics' $129M IPO

    Early-stage biotechnology firm Scribe Therapeutics began trading publicly on Friday after raising $129 million in its upsized initial public offering steered by Fenwick & West LLP and Latham & Watkins LLP.

  • July 24, 2026

    Top Product Liability Cases Of 2026: Midyear Report

    In one of the most-watched cases for product liability so far this year, the U.S. Supreme Court ruled that failure-to-warn claims about the alleged cancer risks of Monsanto's widely used pesticide Roundup are barred by federal law. Social media titans were also rocked by the first verdicts delivered in cases alleging mental health harms to youth.

  • July 24, 2026

    CVS Seeks Toss Of Hospitals' 340B Suits In NY, Mich.

    CVS urged New York and Michigan federal courts to toss separate suits brought by hospital operators accusing the health giant of diverting savings from the federal 340B Drug Pricing Program to itself, saying the suits purport to raise key questions about the program when they actually concern simple contract disputes.

  • July 24, 2026

    Former Drug Co. Akorn Gets OK For $18.5M Ch. 7 Settlement

    A Delaware bankruptcy judge has signed off on a deal resolving a $28.3 million claim by the buyer of defunct drug developer Akorn's assets, allowing an $18.5 million claim in the Chapter 7 case.

  • July 23, 2026

    Texas Panel Overturns Abortion Injunction Against Midwife

    A Texas appellate court overturned a temporary injunction against a licensed Houston-area midwife accused by state prosecutors of violating Texas' abortion ban, finding Thursday a trial court wrongly admitted probable-cause affidavits from a related criminal case.

  • July 23, 2026

    AstraZeneca Immune In Vax Trial Contract Suit, 10th Circ. Says

    The Tenth Circuit on Thursday overturned a lower court ruling that AstraZeneca lacked immunity from an experimental COVID-19 vaccine trial participant's lawsuit seeking medical compensation after she suffered debilitating injuries, saying a federal statute providing immunity for vaccine developers covers her contract breach claims.

  • July 23, 2026

    Abbott Labs Accused Of Lax Security Over Shinyhunters Hack

    Abbott Laboratories and Exact Sciences were hit with a proposed class action in Illinois federal court Wednesday over a cyberattack carried out by a notorious ransomware gang known as "Shinyhunters" that absconded with patients' medical records, which the suit says is far more harmful than standard identity theft.

  • July 23, 2026

    Mo. Panel Says Exclusion Bars Mallinckrodt Opioid Coverage

    A Missouri appellate court upheld a win for a group of insurers on their arguments that a "your products" policy exclusion applied to bar coverage of alleged damages from drugmaker Mallinckrodt's unbranded marketing of opioid products.

  • July 23, 2026

    Kirkland, Sullivan & Cromwell Steer $2B ArisGlobal Deal

    Dassault Systèmes has agreed to acquire ArisGlobal, an AI-driven software provider for the life sciences industry, from private equity firm Nordic Capital for up to $2 billion, the companies said Thursday.

  • July 23, 2026

    Philly Judge Says Keller Postman Slowing Zantac Litigation

    A Pennsylvania state court judge has said Keller Postman LLC's "crusade" to remove him from presiding over several matters has ground to a halt the Zantac cancer mass tort in Philadelphia, leaving the plaintiffs' cases to "languish."

  • July 23, 2026

    J&J's Delays Should End $25M Asbestos Appeal, Builder Says

    A western Massachusetts real estate developer has asked a Connecticut appeals court to toss Johnson & Johnson's appeal of a $25 million asbestos cancer verdict in his favor, saying the company has yet to file an opening brief despite receiving five deadline extensions.

  • July 22, 2026

    J&J Talc Plaintiffs Must Back Up Cancer Link Or Risk MDL

    Plaintiffs alleging Johnson & Johnson's talcum powder products caused ovarian cancer must show they can offer expert opinions on the link between the disease and talc use or risk having their lawsuits tossed, a New Jersey federal judge ruled Wednesday.

  • July 22, 2026

    Late Emails Undercut BCBS Pricing Suit, Walgreens Says

    Walgreen Co. is urging an Illinois federal judge to again sanction a Blue Cross Blue Shield insurer and its subsidiary for allegedly failing to produce key email evidence the pharmacy retailer says "upends" the insurers' 6-year-old claim that it intentionally overcharged them for prescription drugs.

  • July 22, 2026

    Organ Network, Hospital Sued Over Racial Kidney Criteria

    A kidney disease patient launched a proposed class action in Washington federal court Tuesday accusing the United Network for Organ Sharing and Seattle hospital operator Swedish Health Services of using a flawed race-based adjustment when scoring kidney functioning, hindering Black patients' chances of getting a transplant for years.

  • July 22, 2026

    TransMedics Sheds Some Claims In Organ Transfer Biz Suit

    A Massachusetts federal judge on Tuesday significantly trimmed a proposed shareholder class action alleging that medical technology company TransMedics Inc. and its top brass made misleading statements about the success and cost-effectiveness of its organ donation products and services.

  • July 22, 2026

    Boston Scientific Settles With Stryker In Spine Device IP Fight

    Boston Scientific and Stryker Corp. have reached a settlement to resolve a case in New Jersey federal court over Stryker's alleged efforts to create a back pain device that infringed a Boston Scientific patent.

  • July 22, 2026

    Safety-Net Clinics Defend Insulin Suit Revival To Justices

    Safety-net healthcare providers urged the U.S. Supreme Court not to take on the revival of their proposed antitrust class action against Sanofi-Aventis, Eli Lilly, Novo Nordisk and AstraZeneca, arguing Wednesday that the Second Circuit's decision was based on neither mere trade group lobbying nor any kind of overcharge.

  • July 22, 2026

    Candid Health Wraps $120M Series D Funding Round

    Autonomous revenue cycle management platform Candid Health, advised by Lowenstein Sandler LLP, on Wednesday revealed that it raised $120 million in its latest funding round, marking a three-times increase in valuation over the San Francisco-based company's previous funding round in February 2025.

  • July 22, 2026

    Fed. Circ. Panel Stands By Invalidated Spinal Fusion IP

    The Federal Circuit on Wednesday said it won't rethink a panel's decision invalidating patent claims covering parts used to make expandable implant devices in spinal fusion surgeries that were the basis of a $9.5 million jury verdict against Life Spine Inc.

  • July 22, 2026

    2 Charged In Alleged $52.7M COVID-19 Tax Scheme

    Two men have been indicted in Pennsylvania on allegations that they participated in a multistate conspiracy to bilk the government out of $52.7 million in a COVID-19-related false tax return scheme, according to federal prosecutors.

  • July 22, 2026

    Squires Grants 4 IPRs, Issues No Discretionary Denials

    U.S. Patent and Trademark Office Director John Squires has granted four more petitions for inter partes review, bringing his institution rate to just shy of 30%.

Expert Analysis

  • Opinion

    PTAB Needs Reform To Protect Inventors From Larger Cos.

    Author Photo

    The Promoting and Respecting Economically Vital American Innovation Leadership Act is necessary because it will impose additional requirements on patent validity challenges and prevent large corporations from taking advantage of the Patent Trial and Appeal Board to overwhelm small inventors with repeated litigation, says Eb Bright at ExploraMed Development.

  • FDA User Fee Talks Offer Clues On Upcoming Reforms

    Author Photo

    As the U.S. Food and Drug Administration undergoes the User Fee Act reauthorization process and renegotiates its user fee agreements over the next several months, the agency's consultation meetings with relevant industries can shed light on the FDA's priorities, and provides stakeholders an opportunity to participate in the reform process, say attorneys at Holland & Knight.

  • Moderna Case Highlights Overlooked Hurdle In Biopharma IP

    Author Photo

    The recent settlement of the patent litigation involving Moderna's COVID-19 vaccine in Delaware federal court shows that patent portfolios covering enabling platform technologies can create significant freedom-to-operate risk even when their owners are not direct competitors developing the therapeutic product, says Olga Berson at Thompson Coburn.

  • FDA Framework For Personalized Therapies Raises Questions

    Author Photo

    The U.S. Food and Drug Administration's new plausible mechanism framework for developing individualized therapies reflects the agency's focus on rare-disease drugs, but numerous significant, unresolved issues cast uncertainty on how effective the framework will be in practice, say attorneys at Ropes & Gray.

  • Emissions Permits May Not Override Pollution Exclusions

    Author Photo

    Two recent coverage rulings from the Illinois Supreme Court and the Third Circuit suggest a trend among appellate courts to deny coverage under pollution exclusions, even when the emissions happened pursuant to a government permit, say attorneys at Simpson Thacher.

  • 5 Tips For Navigating Your Firm's All-Attorney Summit

    Excerpt from Practical Guidance
    Author Photo

    Law firm retreats should be approached strategically, as they present valuable opportunities to advance both the firm's objectives and attorneys' professional development through meaningful participation, building and strengthening internal relationships, and proactive follow-up, says James Argionis at Cozen O’Connor.

  • Series

    Coaching Soccer Makes Me A Better Lawyer

    Author Photo

    Coaching youth soccer for my 7-year-old son's team has sharpened how I communicate with clients, prepare witnesses, work within teams and think about leadership, making me a more thoughtful and effective lawyer in many ways, says Joshua Holt at Smith Currie.

  • Series

    Law School's Missed Lessons: The Human Element

    Author Photo

    Law school teaches you to quickly apply intellect and logic when handling a legal issue, but every fact pattern also involves a person, making the ability to balance expertise with empathy critical to the growth of relationships with clients, colleagues and adversaries, says Rachel Adcox at Adcox Strategies.

  • Avoid The Unexpected When Drafting License Agreements

    Author Photo

    The Delaware Court of Chancery's recent decision in Commave v. Zevrain raises several practice points for attorneys drafting commercial contracts, underscoring the importance of considering anti-assignment provisions, specific exclusions and potential carveouts when drafting license agreements or other commercial contracts, say attorneys at Hogan Lovells.

  • CMS Healthcare Enforcement Initiatives May Cause Disruption

    Author Photo

    The Centers for Medicare & Medicaid Services' recently announced enforcement actions against healthcare fraud mark a significant escalation, and CMS' prior approach in the hospice sector suggests that even compliant providers and suppliers should brace for impact, say attorneys at Morgan Lewis.

  • The Benefits Of Choosing A Niche Practice In The AI Age

    Author Photo

    As artificial intelligence becomes increasingly accessible, lawyers with a niche practice may stand out as clients seek specialized judgment that automation cannot replicate, but it is important to choose a niche that is durable, engaging and a good personal fit, says Daniel Borneman at Lowenstein Sandler.

  • How PBMs Can Adapt To Plan Sponsors' Disclosure Demands

    Author Photo

    As federal reforms, growing state regulation and litigation threats push plan sponsors to expect visibility into revenue streams, pharmacy benefit managers should leverage transparency strategically, including by simplifying how they get paid, offering clients audit-ready data and co-designing contracts that are easy for fiduciaries to explain and defend, says Kristie Blase at Frazer + Blase.

  • What New Animal Welfare Enforcement Push Means For Cos.

    Author Photo

    The Trump administration's recently announced multiagency focus on violations of the Animal Welfare Act and related laws will likely lead to broader enforcement actions across industries, heightened scrutiny of compliance standards and a need for businesses to adopt effective risk management practices, says Shennie Patel at Crowell & Moring.

  • How To Engage With Gov't's Direct-To-Consumer Drug Policy

    Author Photo

    The U.S. Department of Health and Human Services' recent request for industry input on manufacturers' direct-to-consumer drug sales reflects the government's caution in this arena, and allows stakeholders a rare opportunity to help shape policy, says Mary Kohler at Kohler Health Law.

  • Series

    Podcasting Makes Me A Better Lawyer

    Author Photo

    Podcasting has changed how I ask questions and connect with people, sharpening my ability to listen without interrupting or prejudging, and bringing me closer to what law is meant to be: a human profession grounded in understanding, judgment and trust, says Donna DiMaggio Berger at Becker.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.